Nishihara and her colleagues examined the association between aspirin use and colorectal cancer's BRAF
mutation status using data from two large national prospective cohort studies that tracked participants' aspirin use beginning in the 1980s.
Dabrafenib, a BRAF
inhibitor, was approved for patients with unresectable or metastatic melanoma with the BRAF
V600E mutation as detected by an FDA-approved test.
Flaherty, MD, Director of Developmental Therapeutics at Massachusetts General Hospital, involved 322 patients who had the specific BRAF
mutation and advanced melanoma.
In August 2011, vemurafenib was FDA-approved as a chemotherapeutic drug for the treatment of metastatic melanoma patients harboring the BRAF
The cobas BRAF
Mutation Test is a companion diagnostic developed by Roche to identify patients with melanoma tumors that carry a mutated form of the BRAF
gene, and will be eligible for treatment with Zelboraf (vemurafenib), once it is commercially available.
Out of 32 patients with the BRAF
mutation in the trial, 81% showed complete or partial shrinkage of tumors.
The drug, PLX4032, inhibits faulty BRAF
and prevents it stimulating the cancer.
KRAS or BRAF
mutations are present in nearly half of CRC tumors.
Our study shows that the genetic damage of BRAF
is the first step in skin cancer development.
According to the university's research group, the congenital abnormality of KRAS and BRAF
induces CFC syndrome, a rare genetic disorder characterized by a distinctive facial appearance, congenital cardiac lesion, mental deficiency, and excessive keratinization.
Although these predominantly male risk factors correlate with and may at least partially explain the higher incidence of melanoma in males versus females, the mechanism behind this sex-linked effect remains unclear, as does the role of BRAF
aberrations in the etiology of melanoma.
The investigators found BRAF
mutations in a range of other human cancers, although the gene alterations weren't as frequent.